Allay Therapeutics Announces First Patients Dosed in Pivotal Phase 2b Registration Trial of ATX101 for Post-Surgical Pain Management After Knee Replacement Surgery
ATX101 is designed to provide extended pain relief after surgery, reducing the need for opioids and improving patient recovery
Phase 2b registration trial is assessing the efficacy and safety of ATX101 for post-surgical pain management in total knee replacement patients and is currently enrolling across U.S. clinical sites
Maruishi Pharmaceutical, Allay's partner in Japan also has enrolled first several patients in Phase I/II open-label study
SAN JOSE, Calif., February 18, 2025--(BUSINESS WIRE)--Allay Therapeutics, a clinical-stage biotechnology company pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation, today announced that the first patient has been dosed in its Phase 2b registration trial evaluating ATX101 for the treatment of post-surgical pain following total knee replacement (TKA) surgery. ATX101 is a novel investigational analgesic that provides extended pain relief after surgery, reducing the need for opioids and improving patient recovery.
"We're thrilled to achieve this important milestone with the patients dosed in our Phase 2b registration trial of ATX101," said David Hewitt, Chief Medical Officer at Allay Therapeutics. "This trial is a significant step forward on our path to changing the paradigm of postoperative pain management by providing a simplified locally targeted solution that provides sustained analgesia in the weeks following surgeries. Building on promising data from our earlier dose-ranging studies, we are excited to see how ATX101 can help improve patient outcomes, reduce opioid use and improve function more rapidly than currently available therapies."
The Phase 2b registration trial of 200 participants undergoing total knee arthroplasty (replacement, or TKA surgery) is being conducted at multiple U.S. sites and is a three-arm, randomized, controlled study evaluating treatment with ATX101 1,500 mg versus placebo and bupivacaine active comparator. A prior dose-ranging Phase 2b trial achieved clinically meaningful durable treatment effects with ATX101 versus standard-of-care bupivacaine based on pain intensity out to four weeks, with less use of opioids and meaningful improvement in functional activities up to 60 days following surgery.
Allay Therapeutics' Japanese partner Maruishi Pharmaceutical has also dosed the first patient in January in a Phase I/II multi-center open-label safety study of ATX101 in Japan. Initial clinical data from both studies is expected to be shared in the second half of 2025.
About ATX101
ATX101 is a novel investigational configuration of an approved, well-characterized, validated intracellular sodium ion channel blocker, bupivacaine, and a biopolymer that has been designed to provide weeks of pain relief following total knee arthroplasty (TKA, or replacement), a common orthopedic surgery. ATX101 has a high density of drug within its small footprint to allow for ultra-sustained analgesia. It is placed in minutes at the end of standard surgery to deliver its analgesic effect over weeks before eventually dissolving into water and carbon dioxide. The simple procedure does not require specialized training and is intended to replace the existing complex mix of analgesic products used for shorter-term pain management in the post-surgical setting. ATX101 is an investigational product that has not been approved by the U.S. Food and Drug Administration.
About Allay Therapeutics
Allay Therapeutics is pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation for patients and physicians. Our proprietary technology platform combines validated non-opioid analgesics and biopolymers to create dissolvable candidates to deliver pain relief within a targeted site over weeks: an order of magnitude greater than the longest-lasting pain treatments currently available. Our platform and vision were shaped by The Foundry incubator and Lightstone Venture's Singapore Fund. Allay unites a dynamic, global team of entrepreneurs, scientists, clinicians and innovators in the San Francisco Bay Area and Singapore. Learn more at allaytx.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250218367829/en/
Contacts
For further details, please contact: Investors Adam Gridleyadam.gridley@allaytx.com
Media allay@tenbridgecommunications.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
E&E News
an hour ago
- E&E News
US grid operator leverages AI to speed power plant connections
The grid operator for the Great Plains region on Thursday announced an agreement with Japanese conglomerate Hitachi that aims to use artificial intelligence to speed up the rate at which new power projects can come online. The Southwest Power Pool, which runs the high-voltage grid across parts of 14 states from Texas to the Canadian border, aims to slash the time it takes to connect new power projects to by as much as 80 percent. Like other regions of the country, SPP is grappling with convergence of trends that's putting pressure on the power industry. Aging fossil fuel plants are being retired at a faster rate than new renewable and natural-gas-fired projects can come online. And demand is surging because of new manufacturing plants, data centers and electrification of cars and space heating and extreme weather is showing up more frequently. Advertisement Nationally, data centers are projected to consume as much as 12 percent of the nation's electricity by 2028 — almost triple the share a couple years ago, according to the Energy Department. SPP said without action, its reserve margins — a buffer to guard against outages when power plants trip offline — could drop to 5 percent in 2029 from 24 percent in 2023, raising the possibility of power shortages during emergencies.
Medscape
an hour ago
- Medscape
Small Ear-Wax Sample, Big Diagnostic Clues
A recent BBC report suggests that cerumen, commonly known as earwax, may harbor biomarkers to aid in the diagnosis and monitoring of conditions such as cancer, Alzheimer's disease, and metabolic disorders. Cerumen Profile The primary function of cerumen is to keep the external auditory canal clean and lubricated, preventing invasion by bacteria, fungi, and insects. Beyond this, cerumen may reflect systemic metabolism by concentrating a broader array of compounds than blood, urine, sweat, and tears. Its relative stability allows the accumulated cerumen to provide long-term snapshots of metabolic changes. Disease Associations Researchers have defined genetically determined wet and dry cerumen phenotypes. In the US, Caucasian, African American, and German women with wet cerumen faced roughly four times the risk of dying from breast cancer compared with Japanese and Taiwanese women with dry cerumen. The study found that Japanese women with breast cancer were more likely to carry the wet-cerumen allele than were healthy controls. However, large-scale studies in Germany, Australia, and Italy failed to confirm these associations. A recent analysis reported that patients with Ménière's disease had lower levels of three fatty acids in the cerumen compared with healthy controls — the first biomarker identified for that disorder. In a 2019 study led by Nelson Roberto Antoniosi Filho, PhD (Federal University of Goiás Goiânia in Brazil), researchers analyzed cerumen samples from 52 patients with lymphoma, carcinoma, or leukemia and 50 healthy volunteers, using a method that identifies volatile organic compounds (VOCs). The researchers identified 27 VOCs that served as diagnostic fingerprints for cancer, predicting the cancer status with 100% accuracy. The assay could not distinguish among cancer types, indicating that these VOCs represent a general response to malignant cells. Another investigation by the same group showed that cerumen analysis can detect metabolic disturbances in premalignant stages when cells exhibit dysplastic changes that may lead to cancer but remain nonmalignant, potentially enabling much earlier intervention. The team is also investigating whether metabolic alterations caused by neurodegenerative diseases, such as Parkinson's disease and Alzheimer's disease, can be detected in the cerumen. Diagnostic Tool Antoniosi Filho and colleagues proposed that cancer, as a mitochondrial metabolic disorder, releases VOCs that accumulate in cerumen, allowing differentiation between healthy and cancerous individuals via an assay they call the cerumenogram. The aim was to develop a cerumenogram as a diagnostic tool to accurately predict certain cancers from a small cerumen sample. Clinical Adoption Hospital Amaral Carvalho in Jaú, São Paulo — a national reference center for oncology and bone marrow transplantation — has recently implemented cerumenograms for cancer diagnosis and monitoring. Future Directions An April 2025 paper in Scientific Reports by Antoniosi Filho concluded that the cerumenogram could: 1. Identify oncologic risk by detecting premalignant cells before cancer onset, introducing a novel screening modality 2. Show that mitochondrial impairment in premalignant cells — such as hypermetabolic inflammation and dysplasia — produces the same VOC biomarkers as malignant cells, distinct from those in benign lesions, opening new paths for risk management and early intervention 3. Correlate cerumenogram findings with established imaging techniques such as 2-deoxy-2-[fluorine-18] fluoro-D-glucose PET/CT (18F-FDG PET/CT) and gallium-68 PSMA PET/CT, demonstrating alignment with clinical results while offering a noninvasive, lower-cost alternative 4. Monitor treatment response and cancer remission, supporting assessment of therapeutic efficacy and cellular return to normal 5. Confirm metabolic indicators of malignancy to guide clinical decisions alongside imaging and biopsy 6. Drive the development of targeted therapies aimed at metabolites overproduced in malignant conditions. In conclusion, the cerumenogram may serve as a valuable assay for evaluating precancerous indicators, cancer progression, and remission, with the potential to reduce mortality, alleviate patient suffering, and lower disease-related costs. Congratulations to Nelson Roberto Antoniosi Filho, PhD, and his team.
San Francisco Chronicle
2 hours ago
- San Francisco Chronicle
Their Wine Country restaurant is a hot destination. Their new spot is for the locals
The team behind one of Sonoma County's best restaurants will soon open a new, more approachable spot in Petaluma. Named Bijou — 'jewel,' in French — it is the latest from Table Culture Provisions owners Stéphane Saint Louis, Steven Vargas and Marta Saint Louis. At 190 Kentucky St. starting Friday, June 13, diners will find seasonal dishes applying French technique to the North Bay's wealth of seasonal produce, but at a lower price than the group's original restaurant. Table Culture Provisions is beloved by visitors and locals, who often refer to it simply as TCP. But with a tasting menu that runs in the triple digits and can only accommodate around a 10 tables, it's not easily accessible. 'That is a barrier for the community to come in every day, or once a week,' said Saint Louis, who will run the kitchen at the new restaurant while Vargas helms TCP. 'At Bijou, you'll have food at the quality and standard of what we offer at Table Culture Provisions, just more affordable and approachable.' (The restaurant did not provide prices for dishes.) Snacks and shared dishes will include tempura vegetable batons with a green goddess drizzle and sprinkled with malt vinegar powder, and a petit croque monsieur with shaved truffles on top. The Cowgirl x D. Fatti is a rosemary boule from local bakery Della Fattoria hollowed out and stuffed with Cowgirl Creamery's funky-rich Red Hawk cheese that's topped with roasted garlic and a drizzle of honey. The bread's interior is cut into stubby sticks, then fried, the better to dip into the soft cheese. Larger entrees will include a 10-ounce rib eye from San Rafael butchers Flannery Beef in a black peppercorn sauce, cut into thin slivers that give it a classic French bistro feel. A small side of bone marrow truffle fries and a small salad with shaved Parmesan come along with the cut. A Japanese sea bream will be served with a vegetable ragout and a pistachio caper sauce. Hand-made stuffed pastas will rotate frequently, starting with caramelle, pasta bundles with twisted ends akin to a wrapped caramel. These come stuffed with Liberty duck legs cured in a cumin-fennel blend then confited overnight. Staff baste the caramelle with a jus made from duck stock and duck bones that's spiked with a hit of Port. A zigzag of rich crème fraîche and pea tendrils accent the dish. 'I'm just a fan of stuffed pastas and I take pride in making these,' Saint Louis said. He's already looking forward to future pastas such as a tortellini filled with hearty beef cheeks during the colder months of the year, and agnolotti stuffed with locally caught Dungeness crab when the next season begins. Dessert at Bijou from Table Culture Provisions pastry chef Sylvain Parsy includes a mille feuille, the classic French dessert of layered puff pastry and vanilla cream, that's textured with burnt caramel and a ribbon of creme anglaise. A flight of petit fours, assorted bite-sized sweets, will come in triplets or quartets paired with coffee or tea. Once summer strawberries arrive at the restaurant they will go into a tart topped with rhubarb sorbet. Until then, there's a sundae that's topped with shaved almond, cacao nib and a pour of fresh, hot chocolate sauce. Otello Tiano, who led the bar program at San Francisco's Lazy Bear, consulted on Bijou's drinks. The cocktail list will include six original cocktails and six classics with a French inclination, using ingredients like Chartreuse and pastis, a liqueur flavored with anise. Wines will be diverse, with various styles and origins, but with a focus on California. Bijou took over the former home of southern restaurant Easy Rider, known for its fried chicken and mac-and-cheese, which closed in December. The space can accommodate 55 seated diners, making a dinner reservation or a walk-in a lot more feasible than at TCP. Plans are to open every day, except Wednesdays, for dinner service, with regular Sunday brunch. A daytime window, Café Bijou, will offer pastries, sandwiches, salads and a soup du jour, plus coffee using beans from local roaster Petaluma Coffee & Tea Co. Saint Louis described the interior as feeling like 'modern comfort,' with its whitewashed walls, concrete bar and minimalist tables. Exposed brick supports and warm light from metal frame chandeliers help the building a cozier, he said. 'It's my jewel box for the community.'
